Skip to main content
Premium Trial:

Request an Annual Quote

The BioCommerce Week Index: Apr 14, 2005

BioCommerce Week’s Index to the
Diversified Molecular Biology Tools Companies
Company
Ticker
Current Price
(April 12, 2005)
Last Price
(
April 5, 2005)
% Change
Agilent
A
21.36
21.36
0.00
Applied Biosystems
ABI
20.69
19.82
4.39
BD
BDX
58.51
58.09
0.72
Beckman
BEC
67.33
67.28
0.07
Bio-Rad
BIO
50.05
50.00
0.10
Bruker
BRKR
3.6
3.68
-2.17
GE
GE
36.09
35.5
1.66
Harvard Bio
HBIO
3.81
3.81
0.00
Invitrogen
IVGN
72.33
69.72
3.74
Molecular Devices
MDCC
19.88
19.01
4.58
PerkinElmer
PKI
20.4
20.32
0.39
Sigma
SIAL
60.55
61.00
-0.74
Stratagene
STGN
8.65
8.88
-2.59
Thermo
TMO
24.85
24.99
-0.56
Waters
WAT
36.16
35.7
1.29
Index Average 
33.62
33.28
1.02

Waters Shares End Four-Week Skid With 1.3 Percent Gain

After four weeks of consecutive losses, including a 23-percent loss last week, shares of Waters finished the five-day period ending Tuesday up 1.3 percent. This restored a fraction of the more than $1 billion in the company's market cap erased last week following the company's downward projection of its first-quarter financial results (see BCW 4/7/2005).

Shares in Molecular Devices, which launched two ADME screening kits, finished the week up 4.6 percent to lead the 15 companies whose shares are tracked in the weekly BCW index, while Applied Biosystems (see related article) was up 4.4 percent.

Stratagene, with a 2.6 percent loss, led four companies whose shares fell, closing at $8.7 after announcing the hire of a new senior vice president of marketing.

The index ended a four-week string of losses, finishing up 1 percent at $33.62 from last week's $33.28 close and outperforming the S&P 500, the Dow, and the Amex Pharma indices, which closed the period gaining a fraction of a percent, while the Nasdaq index was down a fraction. The Amex Biotech index finished the period up nearly 4 percent.

File Attachments
The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.